Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.

Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billion, which will be used “primarily for debt paydown and general corporate purposes.”

Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora, Inc. (NYSE:COR ) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Eric Percher - Nephron Research Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Daniel Grosslight - Citi George Hill - Deutsche Bank Stephanie Davis - Barclays Eric Coldwell - Baird Kevin Caliendo - UBS Operator Good morning and good afternoon, ladies and gentlemen. Welcome to the Cencora Q3 Earnings Call.

Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago.

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.